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Simple Summary: The accessory sex glands are responsible for producing seminal plasma, and thus
play a vital role in reproduction and fertility. While the horse rarely suffers from some of the accessory
sex gland diseases affecting other domesticated animals, glandular secretions can nonetheless affect
semen quality and survival, and little is known about the effects of steroid hormones on glandular
development and regulation. This study assessed the expression level and distribution of the steroid
receptors AR, ESR1, and ESR2, and the steroidogenic enzymes 3BHSD, CYP17, and CYP19 in the
equine accessory sex glands at various stages of life and demonstrated that sex steroid receptors
are present in all equine glands throughout life. In contrast, steroidogenic enzymes were only
weakly and variably expressed, suggesting that the accessory sex glands are not significant sites
of steroidogenesis.
Abstract: The expression pattern and distribution of sex steroid receptors and steroidogenic enzymes
during development of the equine accessory sex glands has not previously been described. We
hypothesized that equine steroidogenic enzyme and sex steroid receptor expression is dependent
on reproductive status. Accessory sex glands were harvested from mature stallions, pre-pubertal
colts, geldings, and fetuses. Expression of mRNA for estrogen receptor 1 (ESR1), estrogen receptor
2 (ESR2), androgen receptor (AR), 3β-Hydroxysteroid dehydrogenase/∆5-4 isomerase (3βHSD),
P450,17α hydroxylase, 17–20 lyase (CYP17), and aromatase (CYP19) were quantified by RT-PCR, and
protein localization of AR, ER-α, ER-β, and 3βHSD were investigated by immunohistochemistry.
Expression of AR, ESR2, CYP17, or CYP19 in the ampulla was not different across reproductive
statuses (p > 0.1), while expression of ESR1 was higher in the ampulla of geldings and fetuses than
those of stallions or colts (p < 0.05). AR, ESR1 and ESR2 expression were decreased in stallion
vesicular glands compared to the fetus or gelding, while AR, ESR1, and CYP17 expression were
decreased in the bulbourethral glands compared to other glands. ESR1 expression was increased
in the prostate compared to the bulbourethral glands, and no differences were seen with CYP19 or
3β-HSD. In conclusion, sex steroid receptors are expressed in all equine male accessory sex glands in
all stages of life, while the steroidogenic enzymes were weakly and variably expressed.
Keywords: stallion; fetus; prostate; ampulla; vesicular gland; bulbourethral gland
1. Introduction
Accessory sex glands are located in the pelvic inlet and are primarily responsible for
producing seminal plasma [1]. The presence, size and shape of the glands vary among
Animals 2021, 11, 2322. https://doi.org/10.3390/ani11082322 https://www.mdpi.com/journal/animals
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domesticated mammals, with all accessory sex glands present in pairs (ampulla, vesicular
glands, and bulbourethral glands) or lobules (prostate) in the horse [1]. In equids, the
ampulla is a prominent dilation of the vas deferens averaging 10–25 cm in length, 1–2 cm
in width, and with a 2 mm luminal diameter [1,2]. During emission, sperm stored in
the tail of epididymis is transported to the lumen of the ampulla via vas deferens, then
forceful contractions of the ampulla during ejaculation evacuate their contents into the
colliculus seminalis [1]. Vesicular glands are sac-like structures located caudal to the ampulla
on either side of the pelvic urethra and are responsible for producing the gel fraction of
equine semen [1]. The prostate is a bi-lobulated gland located alongside the pelvic urethra,
caudal to the vesicular glands, and originates as an outgrowth of the embryonic urogenital
sinus [1]. The final accessory sex glands, the bulbourethral glands, are located at the caudal
end of the pelvic urethra, and are covered by the bulbourethral muscle [1].
While development and regulation of the accessory sex glands is well described in
some species (e.g., dogs) frequently affected by disease of the accessory sex glands, little is
known about the development and function of these glands in the horse, despite the impor-
tant role these glands play in determining fertility in other species. Sex steroid production
and modulation are known to play an important role in reproductive development and
regulation of the male reproductive tract in mammals [3,4]. Androgens are important for
testicular development and maintenance of spermatogenesis in the horse, and presumably
also play a role in accessory sex gland development and function [3]. In humans, androgens
are vital to prostatic growth and tissue homeostasis [4]. The androgen receptor (AR) is
highly expressed in the epithelium of the normal mature canine prostate, and expression
decreases in diseased glands [5]. Given that horses are not prone to prostatic disease [6],
it is possible that androgens do not play a significant role in glandular proliferation in
the horse.
Estrogen plays a variety of roles in the male reproductive tract, from the regula-
tion of resorption of luminal fluid in the efferent ducts [7] to the regulation of protein
secretions [7–9]. Of interest, immunolocalization of ER-α and ER-β in the reproductive
tract differs by species and tissue [7]. For example, while ER-β is found in all three epididy-
mal regions throughout development in stallions, ER-α is less present in the epididymis of
pre-pubertal animals and more prominent in post-pubertal animals [10]. This change corre-
sponds with an increase in estradiol and suggests ER-α may be important in maturation of
the reproductive tract at puberty. The relative expression of ER-α and ER-β receptors in
the stallion accessory sex glands is currently unknown.
Estrogens are often produced in peripheral tissues that express aromatase, and it
is possible that the stallion accessory sex glands could be another site of estrogen or
androgen production. 3β-Hydroxysteroid dehydrogenase/∆5-4 isomerase (3βHSD) and
P450c17 (CYP17) are two of the key enzymes regulating testosterone synthesis. Specifically,
CYP17 converts 17α-hydroxyprengnenolone to dehydroepiandrosterone (DHEA), while
3βHSD catalyzes the conversion of ∆5 steroids such as DHEA to ∆4 keto steroids such
as androstenedione, and aromatase is responsible for estrogen synthesis. In humans,
expression of aromatase increases with age and prostatic diseases [4], while in horses it
increases in Leydig cells with age [3]. Similarly, 3βHSD expression and localization changes
with age in the male equine reproductive tract [3]. 3βHSD is highly expressed in the Leydig
cells of mature stallions, and in the seminiferous tubules and Sertoli cells of prepubertal
colts [3]. CYP17 expression is higher in adult stallion testes than prepubertal or pubertal
testes, and immunolabeling localized CYP17 to Leydig cells in the equine testes [3]. Despite
known presence of these enzymes in the equine reproductive tract, enzyme expression in
the accessory sex glands of the horse is unknown.
Furthering our understanding of the role that reproductive hormones play in the
accessory sex glands could not only improve our knowledge of reproductive physiol-
ogy, but also of subfertility in the stallion. In the present study, our objectives were to
characterize the expression and localization of estrogen receptors, androgen receptor, and
steroidogenic enzymes in the equine fetal, pre-pubertal colt, stallion, and gelding accessory
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sex glands. We hypothesized that steroid receptor and steroidogenic enzyme expression
would vary based on life stage in the male equid, and that the accessory sex glands may be
an additional site of steroid synthesis in the horse.
2. Materials and Methods
2.1. Tissue Collection
Accessory sex glands were obtained from adult horses (n = 6) and fetuses (n = 3)
euthanized for other research protocols at the University of Illinois of Illinois Veterinary
Teaching Hospital, in Urbana IL, and from pre-pubertal animals (n = 3) euthanized at
the Maine Chance Research Farm Department of Veterinary Science, University of Ken-
tucky, Lexington, KY. Protocols were approved by the Institutional Animal Care and Use
protocols at the University of Illinois (#1400, #14226, and #14243) and University of Ken-
tucky (#2012-1046). Clinically healthy males were divided into the following groups: fetal
(280–310 days gestation, n = 3), intact pre-pubertal (4, 8, or 10 months; n = 3), intact adult
(4, 9, or 11 years; n = 3), and castrated adult (5, 8, or 13 years, n = 3). Accessory sex glands
(vesicular gland, prostate, ampulla, and bulbourethral gland) were harvested immedi-
ately after euthanasia. Adult and pre-pubertal animals were euthanized via intravenous
administration of pentobarbital sodium overdose. Fetuses were collected after induced
parturition for another study and were euthanized immediately after delivery via intra
cardiac injection of pentobarbital sodium. After euthanasia and en-block dissection of the
reproductive tract from each carcass, tissues were placed on ice until further processing.
Reproductive tract samples were chopped into 0.25 cm pieces, preserved in RNAlater
(Invitrogen, Carlsbad, CA, USA), refrigerated overnight (4 ◦C), then frozen in RNAlater
and stored at −80 ◦C until RNA isolation. Additional glandular samples were placed in
10% neutral buffered formalin for histological and immunohistochemistry analysis.
2.2. qPCR Analysis
The mRNA expression of androgen receptor (AR), estrogen receptor 1 (ESR1), estrogen
receptor 2 (ESR2), 3β-Hydroxysteroid dehydrogenase/∆5-4 isomerase (3βHSD), CYP17
(P450c17), and CYP19 (P450arom) were quantified by real-time quantitative PCR (qPCR)
using primers shown in Table 1 as previously described [3,11]. Tissues were minced into
small pieces using a scalpel blade, and then homogenized using a tissue homogenizer
(Fisher Scientific, Arlington VT, USA). TRIzol Reagent (Invitrogen) was used to extract total
cellular RNA from the samples according to the manufacturer’s recommendation. RNA
was precipitated with isopropanol and 1/10 volume of 3 M sodium acetate, resuspended
in deionized bi-distilled water, and then quantified by spectrophotometry (NanoDrop ND-
1000; Agilent Technologies, Palo Alto, CA, USA). Glandular samples with a 260/280 ratio
greater than 1.95, and a 260/230 ratio of at least 2.0 were used for analysis. For each
reaction, 2 µg of RNA were then treated with rDNaseI (Invitrogen) for 30 min at 37 ◦C,
followed by treatment with DNase Inactivation Reagent at room temperature for 2 min.
A high-capacity cDNA reverse transcription kit and random hexamers (Invitrogen) were
used for reverse transcription. The primers were designed using Primer-BLAST, and SYBR
Green PCRMaster Mix (Invitrogen) was used for quantitative PCR. Cycling conditions
were as follows: 95 ◦C for 10 min, 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min, and
55–95 ◦C for dissociation, all reactions were performed in duplicate, and efficiencies were
calculated using LinRegPCR (version 2012.0).
Reactions were automatically pipetted by the epMotion Automated Pipetting Systems
(Eppendorf, Westbury, NY, USA). Dissociation analysis at the end of each real-time run was
used to verify the amplification of a single product and ensure specificity of amplification.
All changes in gene expression were calculated by mean threshold cycle (CT) and then nor-
malized for the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and ribosomal 18s to generate delta (∆) CT values. All changes in relative abundance of
transcripts were calculated by comparing the expression of the target transcript relative to
the reference transcript ∆-CT method [12].
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2.3. Immunohistochemistry
Protein localization of AR, ER-α, ER-β, and 3βHSD in accessory sex glands were inves-
tigated by immunohistochemistry (IHC) using receptor and enzyme antibodies previously
shown to be validated in the horse [3,10,13], as previously described [3,11]. Accessory
sex gland sections (0.5–1 cm thickness) were fixed in 10% neutral buffered formalin for
24 h. After fixation, all samples were dehydrated and embedded in paraffin, and later sec-
tioned in 5 µm slices for IHC. For immunostaining of tissues, a mouse anti-α-bovine ER-α
monoclonal antibody (1:25, sc-787, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA),
a mouse anti-human estrogen receptor beta (ER-β) 1 isoform monoclonal antibody (1:20,
MCA1974S, AbD Serotec, Raleigh, NC, USA), a goat 3βHSD polyclonal antibody (1:500,
SC-30820, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), and a rabbit anti-human
AR polyclonal antibody (1:1000, SC-816, Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) were selected.
Briefly, the slides were exposed to automated dewaxing and rehydration steps, and
then antigen retrieval was conducted using heat (100 ◦C for 30 min) and a pH 6.0 citrate-
based ready to use solution (Leica Biosystems, Wetzlar, Germany). The slides were subse-
quently incubated with 3% hydrogen peroxide for 5 min, then a diluted primary antibody
for 15 min, followed by a rabbit anti-mouse IgG for 8 min, a polymer-labeled goat anti-
rabbit IgG coupled with horseradish peroxidase for 8 min, and finally a diaminobenzidine
substrate for 10 min with reagents from the Bond Polymer Refine Detection system (Leica
Biosystems). Primary antibodies were diluted to the desired concentration using Bond
Primary Antibody Diluent (Leica Biosystems). The washing steps between each reagent
were performed using Bond Wash solution 10× concentrate (Leica Biosystems) diluted to
a 1× working solution with distilled water. After staining, serial ethanol dilutions were
used to dehydrate all slides, and slides were then immersed in four baths of 100% xylene
and mounted for analysis. Slides were viewed at 40× and 100× magnification for analysis.
2.4. Histology
Five-micron sections of formalin-fixed, paraffin embedded (FFPE) tissue derived
from all glands of each horse at all life stages were stained with Masson’s Trichrome,
hematoxylin, and eosin for structural evaluation following standard procedures.
2.5. Quantitative Analysis of Immunohistochemistry
For the quantification of AR, ER-α, ER-β, images were acquired from each section
in ten different fields at 40× magnification (Uplan Apo 40×/0.85) with a camera (Pro-
gRes C14plus, Jenoptik, Germany) coupled with a microscope (Olympus BX51, Olympus
corporation, Tokyo, Japan).
Images were analyzed using ImageJ (Version 1.52a, National Institute of Health,
Bethesda, MD, USA) and IHC toolbox, a semi-automatic plugin of ImageJ [14]. The
positive colors were manually selected in at least ten random images of each receptor.
A statistical model for the color detection was created and applied to the other images
during the analyses. In each image, pixels stained with the specific color were detected
and extracted from the background. Subsequently, the HSB-threshold function of ImageJ
was used to quantify the percentile of the area occupied by the positive staining.
2.6. Statistical Analysis
Normal distribution of data was confirmed by the Shapiro–Wilk Test, and normal vari-
ance was confirmed with the Bartlett’s test. The ∆CT values for each status and gland were
analyzed by one-way ANOVA, and when significant, post hoc comparisons with Tukey’s
HSD. Similarly, glandular immunolabeling intensity was analyzed by one-way ANOVA
and when significant, post hoc comparisons with Tukey’s HSD. Significance was set at
p < 0.05. Statistical analyses were carried out using R version 4.0.3 (10 October 2020) [15].
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Table 1. Primer sequences for real-time quantitative PCR of equine accessory sex glands [3,16].
Genes (Locus) Primer Sequence Ref.
AR (XM 01504865.1) Forward: 5′-AGCTGCCATCCACTCTGTCT-3′ [11]
Reverse: 3′-TGATAAACTGCTGCCTCGTC-5′
ESR1 (NM 001081772) Forward: 5′-TCCATGGAGCACCCAGGAAAGC-3′ [16]
Reverse: 3′-CGGAGCCGAGATGACGTAGCC-3′
ESR2 (XM 001915519) Forward: 5′-TCCTGAATGCTGTGACCGAC-3′ [16]
Reverse: 3′-GTGCCTGACGTGAGAAAGGA-3′
HSD3B1 (D89666.1) Forward: 5′-AGCAAATACCATGAGCACGA-3′ [3]
Reverse: 3′-TAACGTGGGCATCTTGTGAA-5′
CYP17 (GenBank# D30688.1) Forward: 5′-GCATGCCTGGACTTACTGATCC-3′ [3]
Reverse: 3′-CTGGGCCAGTGTTGTTATTG-5′
CYP19 (Horse Genome #AF031520.1) Forward: 5′-CCACATCATGAAACACGATCA-3′ [3]
Reverse: 3′-TACTGCAACCCAAATGTGCT-5′
3. Results
3.1. Histological Assessment of Accessory Sex Glands
The majority of the fetal ampulla and prostate was stromal, with limited small diameter
ducts lined by few branched tubular glands. The colt prostate and ampulla had a higher
epithelium to stromal ratio, and many sperm were noted in the lumen of the stallion
ampulla. Branching of the tubulo-alveolar glands was maximal in the stallion, and very
blunted with minimal branching in the gelding ampulla, as seen in Figure 1. In contrast,
the tubulo-alveolar glands of the fetal bulbourethral gland were already developed, and
changes between the life stages was minimal. Some tubular dilation was noted in the
gelding bulbourethral gland. In contrast to the bulbourethral gland, the vesicular glands
were mainly connective tissue in the fetus, colt, and gelding, and columnar glands were
only extensive in the stallion, as can be seen in Figure 2.
Figure 1. Representative images of the accessory sex glands of the fetus stained with hematoxylin
and eosin (A) 280 days gestation, prepubertal colt (B) 4–10 months, mature stallion (C) >5 years, and
gelding (D) >5 years.
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Figure 2. Representative images of the accessory sex glands stained with Masson’s Trichrome stain.
Glands pictured come from a male fetus (A) 280–310 days gestation, prepubertal colt (B) 4–10 months,
mature stallion (C) >5 years, and gelding (D) >5 years.
3.2. Androgen Receptor
AR mRNA expression did not differ between reproductive stages in the ampulla,
bulbourethral, or prostate glands (p > 0.05), as can be seen in Figure 3. In the vesicular
gland, AR expression was significantly higher in the fetus than in the stallion (p < 0.05).
The bulbourethral glands showed the lowest level of AR mRNA expression compared to
the other accessory glands. Similarly, the percentage of cells labeled by IHC, depicted in
Table 2, did not differ between reproductive stages, but the percentage cells labeled were
lower in the vesicular gland than the bulbourethral gland or prostate.
Table 2. Mean positive immunolabeling (%) for Androgen Receptor (AR), Estrogen receptor alpha (ER-α) and Estrogen
receptor beta (ER-β) in male equine accessory sex glands of different life stages (fetus 280-310 days gestation, prepubertal
colt 8-10 months, mature stallion > 5 years, and gelding > 5 years), n = 3 per life stage. Superscripts denote significant
difference (p < 0.05) within that row.
AR
Fetus Colt Gelding Stallion
Ampulla 73.9 ± 25.1 a 63.6 ± 10.1 a 64.8 ± 3.8 ab 56.6 ± 3.3 b
Bulbourethral 83.2 ± 9.9 a 58.8 ± 11.1 b 69.4 ± 0.6 b 65.7 ± 13.0 ab
Prostate 67.4 ± 18.7 a 50.4 ± 10.6 b 75.2 ± 17.3 a 68.0 ± 13.7 a
Vesicular 56.7 ± 8.6 ab 48.5 ± 10.0 ab 41.6 ± 25.9 a 55.4 ± 4.6 b
ER-α
Fetus Colt Gelding Stallion
Ampulla 23.3 ± 8.7 ab 21.3 ± 8.7 a 28.8 ± 8.8 b 46.5 ± 8.8 c
Bulbourethral 35.0 ± 10.6 31.7 ± 21.2 38.5 ± 12.7 38.8 ± 19.2
Prostate 21.5 ± 11.9 a 14.0 ± 8.6 a 16.4 ± 6.0 a 31.0 ± 4.2 b
Vesicular 19.5 ± 4.9 b 16.3 ± 5.0 b 17.5 ± 5.8 b 40.3 ± 11.3 a
ER-β
Fetus Colt Gelding Stallion
Ampulla 64.7 ± 23.5 63.3 ± 18.6 64.3 ± 2.4 67.2 ± 10.6
Bulbourethral 55.8 ± 3.4 a 60.8 ± 7.1 b 64.2 ± 3.8 b 70.2 ± 9.7 b
Prostate 44.0 ± 28.3 a 43.2 ± 26.5 ab 56.4 ± 15.4 b 67.0 ± 17.5 c
Vesicular 22.9 ± 13.1 a 42.4 ± 15.6 a 25.4 ± 16.0 a 62.6 ± 16.7 b
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Figure 3. Mean mRNA expression in male equine accessory sex glands during different life stages (n = 3 per life stage).
Data are expressed as mean ∆CT relative to expression of GAPDH. Within glands, life stages with different superscripts
differ in expression (p < 0.05). Abbreviations: AR, androgen receptor; ESR1, estrogen receptor 1; ESR2, estrogen receptor
2; 3βHSD, 3β-Hydroxysteroid dehydrogenase/∆5-4 isomerase; CYP17, cytochrome P450 17α-hydroxylase/17,20 lyase;
CYP19, P450-aromatase.
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The androgen receptor was strongly localized to the nuclei of the ampulla epithelium
in all life stages, with weaker localization to the epithelial cytoplasm, as can be seen in
Figure 4. There was marked localization to stromal cells of the fetal ampulla and colt
ampulla, while stromal cell labeling of the gelding ampulla was sporadic, with labeling
of some, but the majority of stromal cells. Interestingly, AR was strongly localized to
the prostate epithelial cell nuclei in the fetus and stallion, and was largely absent from
the nuclei of the colt and gelding epithelium. All four life stages had sporadic staining
of prostate stromal cell nuclei. In the bulbourethral gland, AR was strongly localized to
the epithelial cell nuclei in the fetus, colt, and stallion, however, only weakly present in
the gelding epithelium. All life stages had intermittent immunolabeling of stromal cell
nuclei in the bulbourethral gland. Similar to the ampulla, AR was strongly localized to the
epithelial cell nuclei of the vesicular gland for all four life stages, had moderate intermittent
labeling of stromal cell nuclei in the colt and stallion, and weaker intermittent labeling of
fetal and gelding vesicular stroma.
Figure 4. Immunolabeling of AR in the accessory sex glands of the fetus (A) 280–310 days gestation,
prepubertal colt (B) 5–10 months, mature stallion (C) >5 years, and gelding (D) >5 years. AR localized
to the epithelium of glands of all life stages except the colt and gelding prostate, and there was
heterogenous localization to stromal cell nuclei.
3.3. Estrogen Receptor 1
ESR1 mRNA expression was higher in the ampulla of geldings and fetuses than
in colts and stallions, and lower in the stallion vesicular gland than in the other three
reproductive stages (p < 0.05) as shown in Figure 5. No differences in expression were
noted in the bulbourethral or prostate glands. Similar to AR, expression of ESR1 was lower
in the bulbourethral gland than the other three glands.
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Figure 5. Immunolabeling of ER-α in the accessory sex glands of the fetus (A) 280–310 days gestation,
prepubertal colt (B) 5–10 months, mature stallion (C) >5 years, and gelding (D) >5 years. ER-α
localized to the epithelium of glands of all life stages.
In contrast, glandular intensity with ER-α immunolabeling was greatest in the bul-
bourethral gland, and lowest in the vesicular and prostate glands (Table 2). The percentage
of cells with immunolabelling was higher in the stallion ampulla than colt or fetal ampulla,
higher in the stallion prostate than the colt, and higher in the stallion vesicular gland
than the colt, fetal, or gelding vesicular glands. ER-α was localized to the cytoplasm of
the epithelium in all glands, with mild localization to smooth muscle cells, and sporadic
labeling of stromal cell nuclei in the bulbourethral gland.
3.4. Estrogen Receptor 2
ESR2 mRNA expression was lower in the stallion than the colt, fetus or gelding
vesicular glands (p < 0.05) and did not vary between reproductive stages for the ampulla,
bulbourethral, or prostate glands. Glandular expression was decreased in the prostate
compared to the other glands (p < 0.05). With ER-β immunolabeling, the percent of
positively labeled cells did not differ between reproductive statuses in the ampulla or
bulbourethral glands, but was stronger in the stallion than colt prostate, and stronger in
the stallion vesicular gland than other reproductive stages (Table 2). The percentage of
cells that were immunolabeled was significantly higher in the ampulla and bulbourethral
glands than the prostate or vesicular gland.
Immunolabeling of ER-β was strong in the epithelial nuclei and cytoplasm of the
stallion and gelding, and only moderate in the colt and fetus, as seen in Figure 6. In the
bulbourethral gland, ER-β localized to epithelial nuclei in all life stages, with moderate
localization to the epithelial cytoplasm in the stallion and gelding, and sporadic stromal
cell labeling in all life stages. Prostatic and vesicular gland immunolabeling of ER-β was
marked in epithelial nuclei, and moderate in epithelial cytoplasm for all life stages. There
were intermittent stromal cell nuclei labeling.
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Figure 6. Immunolabeling of ER-β in the accessory sex glands of the fetus (A) 280–310 days gestation,
prepubertal colt (B) 5–10 months, mature stallion (C) >5 years, and gelding (D) >5 years. ER-β
localized to the epithelium of glands of all life stages, as well as to stromal cells.
3.5. Steroidogenic Enzymes
Expression of 5α-reductase (CYP17, P450c17) was not different between life stages for
any of the glands, and expression of 5α-reductase was minimal in the bulbourethral glands
compared to the other three glands.
Aromatase expression was similar between life stages in all glands, with the exception
that aromatase expression was not detected in the stallion ampulla and colt bulbourethral
glands. Additionally, expression of aromatase was significantly lower in the bulbourethral
gland that the other glands when looking at all life stages combined (p < 0.05).
3βHSD expression was low in all glands, and was similar between life stages, except
for the gelding ampulla, where expression was undetectable. Expression was higher
in the prostate than in the bulbourethral gland or vesicular gland (p < 0.05). 3βHSD
immunolabeling was very weak to absent for all glands and all life stages.
4. Discussion
The accessory sex glands play a vital, but underdiscussed, role in stallion fertility,
and a better understanding of glandular development and regulation may help improve
fertility in some animals. The objectives of this study were to determine if steroid receptors
were present in all equine accessory sex glands, to determine if steroidogenic enzymes
were present in the equine accessory sex glands, and to determine if receptor and enzyme
expression differed based on age and castration status. As hypothesized, steroid receptors
were detected in all accessory sex glands in all life stages in the horse, with variable changes
in expression throughout development, suggesting that they play a role in accessory sex
gland regulation and function. In contrast, CYP17, CYP19, and 3βHSD expression were
weak to absent in all glands, suggesting that these glands are not a likely site of steroid
synthesis in the horse.
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Androgen receptor mRNA expression varied among life stages and glands. There
was increased expression in the fetal vesicular gland compared to the stallion, and lower
expression in the bulbourethral gland as opposed to other glands. This pattern is consistent
with other tissues in the stallion, such as the epididymis, where AR was present in all
regions throughout development and adulthood [10]. Androgens regulate AR expression
in other species [17,18], and maintain epididymal epithelial cell function and secretion [19].
The consistent expression of AR throughout the stallion accessory sex glands suggests
a similar role in the stallion. The apparent lack of localization to the epithelium in the
gelding prostate and bulbourethral gland suggests that a decrease in androgens in the
castrated male may decrease AR expression in the luminal epithelium without affecting
AR expression the stroma. Similar results have been demonstrated in the dog and human,
where castration or withdrawal of hormone treatment lead to a decrease in epithelial and
stromal AR signaling [20,21]. Dogs treated with antiandrogenic agents also have a marked
decrease in prostatic AR expression [22,23]. In contrast to our findings in the prostate and
bulbourethral gland, AR expression in the gelding ampulla and vesicular epithelium is
similar to the stallion and appears to be independent of castration status.
Both ER-α and ER-β were present in the accessory sex glands of the horse. In the
current study, ER1 mRNA expression was higher in the gelding or fetal ampulla than
the colt or stallion, and lower in the stallion vesicular gland than the other three glands.
However, a higher percent of cells showed ER-α immunolabeling in the stallion ampulla
than the colt or fetus, and localized to the epithelial cytoplasm of all glands, and all stages,
suggesting that unlike the epididymis [10], ER-α may not play a role in the maturation of
the accessory sex glands. This is in contrast to rats, where ER-α was not detected in the
epithelial cells at any life stage, and was only faintly detected in the stroma of neonatal
rats [24]. ER-α localization is variable in the equine epididymis after puberty, localizing
to the caput in all animals, and additionally to the cauda in some animals [10]. ER-α and
ER-β differential localization suggests regional and age-related regulator effects, such as
ER-α being responsible for fluid resorption in efferent ducts (21). It has been suggested that
ER-β may be more important for maintenance and homeostasis of epididymis, and ER-α
may have region-specific effects on luminal fluid and protein secretion on other tissue [10],
and similar effects may be possible in the equine accessory sex glands.
In the horse accessory sex glands, expression of ER-β did not vary between life stages
for any gland besides the vesicular gland, and this difference was once again not seen when
evaluating the percent of cells with positive immunolabeling. With immunolabeling, the
percentage of cells positive for ER-β was increased in the stallion prostate and vesicular
glands. Most interestingly, while overall percentage immunolabeling or mRNA expression
did not change, localization of ER-β in the prostate was different in the stallion and fetus,
compared to the colt and gelding, suggesting the potential for androgen regulation of
ER-β expression in the equine prostate. In contrast, in rats, immunostaining of ER-β in the
prostate epithelial nuclei increases in intensity with age [24].
While the role of ER-α and ER-β in accessory sex gland disease in the horse is not
known; in humans, ER-α activation is associated with aberrant proliferation, inflammation
and prostate cancer [4]. In contrast, ER-β activation appears to mediate beneficial anti-
proliferative, anti-inflammatory, and potentially, anti-carcinogenic effects of estrogen [4].
Similarly, activation of the ER-β receptor in testosterone-treated mice prevents the expected
prostatic hyperplasia and inflammation [25], and when ER-β in knocked out in the mice. In
the current study, no clear difference was determined between ER-α and ER-β that might
indicate a role in glandular regulation, but no animals in the current study were exposed
to exogenous hormones.
Aromatase expression increases in the stallion testis with age [26,27], and it was unex-
pected that we did not see a difference in the accessory sex glands with age. This may be in
part due to the relatively low expression in the glands across all life stages and appears to
indicate that the stallion accessory sex glands are not a significant source of estrogen syn-
thesis and may be one reason that the stallion prostate is not prone to disease. Alternatively,
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it is possible that more sensitive methods may be needed to detect aromatase expression in
the equine accessory sex glands. In humans, early studies did not detect aromatase in the
prostate using biological assays [28,29], but later studies detected aromatase expression
on RT-PCR, and detected enzymatic activity using alternative biochemical assays [30–33].
Laser capture microdissection and separation of prostate epithelial and stromal cells defini-
tively demonstrated aromatase in the human prostate stromal cells, and a lack of aromatase
expression in healthy prostatic epithelial cells, and it is possible similar methods might
detect different results in the horse [34].
Finally, 3βHSD expression was almost undetectable in all accessory sex glands in all
life stages of the male horse, also confirming that the accessory sex glands are not likely to
be a site of significant androgen synthesis in the horse. While this is not unexpected, 3βHSD
has been previously detected via immunohistochemistry in the human prostate [35], and
remains to be explored in other species.
5. Conclusions
In conclusion, AR, ER-α and ER-β are all present in the equine accessory sex glands,
with variable changes in expression throughout development, suggesting that they play
a role in accessory sex gland regulation and function. In contrast, lack of strong CYP17,
CYP19, or 3βHSD expression suggests that the equine accessory sex glands do not play
a significant role in steroid hormone production in the horse.
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